The 韩国健康产业振兴院 (KHIDI, President Cha Soon-do) participated in 'Bio 欧洲 2023' (November 6–8) held in 慕尼黑, 德国, where it promoted the competitiveness of 韩国's 制药 and bio industry, and provided support for 韩国 companies' participation and promotion at Bio 欧洲 in collaboration with the 韩国 制药 and Bio-pharma Manufacturers Association, the 韩国毒性研究所, and the 韩国国家临床试验组织.
Bio 欧洲 is the largest 制药 and bio technology transaction forum in 欧洲. This year's event saw 2,075 companies from 64 countries participate, with 178 韩国 companies attending—the fourth highest participation by country, following 德国, the 美国, and the United Kingdom.
KHIDI announced the selection of 38 companies through a 'Bio 欧洲 Participation Support Program' call-for-entries in July, and the selected companies were provided with partial funding for Bio 欧洲 participation expenses and promotional opportunities through the 韩国 Pavilion booth.
The selected companies included: ▲HLB Life Science ▲Nexcel ▲Next-i ▲Doctor Noah Biotech ▲RudaCure ▲Medipig ▲Brexogen ▲VSPharmtech ▲Vivobzon ▲Owlbio ▲Idyens ▲iBio 韩国 ▲Alginovics ▲Uptera ▲S&N Bioscience ▲HLB ▲HLB Cell ▲NA Vaccine Institute ▲MDHealthcare ▲Autotelic Bio ▲Innobo Therapeutics ▲ISU Abxis ▲Intron Bio ▲Ipcell ▲Genome & Company ▲G2G Bio ▲GTI Bioscience ▲CasCure Therapeutics ▲CoaStm ChemOn ▲Curetis ▲T Karos ▲Pelamed ▲Fosbax ▲ProActek ▲Pinobio ▲PIn Therapeutics ▲Hanwha Pharm ▲Huons.
Source: Medisobiz News (http://www.medisobizanews.com)
